cytarabine has been researched along with Fatty Liver in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hanafusa, T; Kobayashi, K; Nakayama, S; Takubo, T; Tsuji, M; Yokote, T | 1 |
| Abei, M; Hasegawa, Y; Iijima, T; Katsura, Y; Kojima, H; Mukai, HY; Nagasawa, T; Shimizu, S; Suzukawa, K; Yoshida, C | 1 |
| Alvarez-Leite, J; Bambirra, EA; Cara, DC; Nicoli, JR; Ramos, MG; Vieira, EC | 1 |
3 other study(ies) available for cytarabine and Fatty Liver
| Article | Year |
|---|---|
Inappropriate antidiuretic hormone production by leukaemic blasts in acute myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Cytarabine; Fatty Liver; Female; Granulocyte Precursor Cells; Humans; Immunohistochemistry; Leukemia, Myeloid, Acute; Liver; Tomography, X-Ray Computed; Vasopressins | 2009 |
Association of non-alcoholic steatohepatitis (NASH) with chronic neutrophilic leukemia.
Topics: Antimetabolites, Antineoplastic; Biopsy; Cytarabine; Fatty Liver; Female; Humans; Leukemia, Neutrophilic, Chronic; Middle Aged; Treatment Outcome | 2004 |
Protection by short-chain fatty acids against 1-beta-D-arabinofuranosylcytosine-induced intestinal lesions in germfree mice.
Topics: Administration, Oral; Animals; Cytarabine; Disease Models, Animal; Fatty Acids, Volatile; Fatty Liver; Intestinal Diseases; Intestinal Mucosa; Mice; Protective Agents | 1999 |